Italia va avanzando en la legalización gracias al cannabis light
tion-drugs.pdf" title="" target="_blank">study published in The Journal of Health Economics has shown that increased use of cannabis light is significantly reducing the sale of anti-anxiety, depression and sedative medications.
This has produced a rebound effect in the process of legalizing cannabis-related products, as it is logical, pharmaceutical companies are generating a lot of pressure on politicians due to the enormous losses they represent to their companies. In the study, it can be seen that as the sales curve for cannabis products increases, that of pharmaceutical products is significantly reduced, 11.5% less in anxiolytics, 10% in sedatives and 4.8% less in antipsychotics.
As long as it was only young people who consumed cannabis and its derivatives that did not affect their sales, this population group is a minority in medical needs. The problem for pharmaceutical companies is that with normalization, more and more older adults are doing it and discovering that they can reduce the consumption of legal drugs, and even stop them, with the cannabis alternative.
This is normal, cannabis products have minimal side effects, do not create addiction, are inexpensive and, to the tests we refer, very efficient. This is not to say that traditional medicine must be abandoned, but that both doctors and therapists are adding cannabis to prescribed treatments.
